Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck - PubMed

Affiliations

• PMID: 10849448
• DOI: 10.1074/jbc.C000126200

Free article

Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck

J M Lionberger et al. J Biol Chem. 2000.

Free article

Abstract

Bcr-Abl is the constitutively active protein-tyrosine kinase expressed as a result of the Philadelphia translocation in chronic myelogenous leukemia. Bcr-Abl is coupled to many of the same signaling pathways normally regulated by hematopoietic cytokines. Recent work shows that Hck, a member of the Src tyrosine kinase family with myeloid-restricted expression, associates with and is activated by Bcr-Abl. Here we investigated the mechanism of Hck interaction with Bcr-Abl and the requirement for Hck activation in Bcr-Abl transformation signaling. Binding studies demonstrated that the Hck SH3 and SH2 domains are sufficient for interaction with Bcr-Abl in vitro. Hck binding localizes to the Abl SH2, SH3, and kinase domains as well as the distal portion of the C-terminal tail. To address the requirement for endogenous Src family kinase activation in Bcr-Abl signaling, a kinase-defective mutant of Hck was stably expressed in the cytokine-dependent myeloid leukemia cell line DAGM. Kinase-defective Hck dramatically suppressed Bcr-Abl-induced outgrowth of these cells in the absence of cytokine compared with a control cell line expressing beta-galactosidase. In contrast, kinase-defective Hck did not affect cell proliferation in response to interleukin-3, suggesting that the effect is specific for Bcr-Abl. These data show that Hck interacts with Bcr-Abl through a complex mechanism involving kinase-dependent and -independent components and that interaction with Hck or other Src family members is essential for transformation signaling by Bcr-Abl.

Similar articles

• The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.

  Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE, Skorski T. Klejman A, et al. EMBO J. 2002 Nov 1;21(21):5766-74. doi: 10.1093/emboj/cdf562. EMBO J. 2002. PMID: 12411494 Free PMC article.

• The c-Fes protein-tyrosine kinase suppresses cytokine-independent outgrowth of myeloid leukemia cells induced by Bcr-Abl.

  Lionberger JM, Smithgall TE. Lionberger JM, et al. Cancer Res. 2000 Feb 15;60(4):1097-103. Cancer Res. 2000. PMID: 10706130

• The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains.

  Stanglmaier M, Warmuth M, Kleinlein I, Reis S, Hallek M. Stanglmaier M, et al. Leukemia. 2003 Feb;17(2):283-9. doi: 10.1038/sj.leu.2402778. Leukemia. 2003. PMID: 12592324

• Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.

  Sattler M, Scheijen B, Weisberg E, Griffin JD. Sattler M, et al. Adv Exp Med Biol. 2003;532:121-40. doi: 10.1007/978-1-4615-0081-0_11. Adv Exp Med Biol. 2003. PMID: 12908554 Review.

• Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL.

  Sattler M, Salgia R. Sattler M, et al. Cytokine Growth Factor Rev. 1997 Mar;8(1):63-79. doi: 10.1016/s1359-6101(96)00047-0. Cytokine Growth Factor Rev. 1997. PMID: 9174663 Review.

Cited by

• Co-expression vs. co-infection using baculovirus expression vectors in insect cell culture: Benefits and drawbacks.

  Sokolenko S, George S, Wagner A, Tuladhar A, Andrich JM, Aucoin MG. Sokolenko S, et al. Biotechnol Adv. 2012 May-Jun;30(3):766-81. doi: 10.1016/j.biotechadv.2012.01.009. Epub 2012 Jan 28. Biotechnol Adv. 2012. PMID: 22297133 Free PMC article. Review.

• Development and targeted use of nilotinib in chronic myeloid leukemia.

  Fava C, Kantarjian H, Cortes J, Jabbour E. Fava C, et al. Drug Des Devel Ther. 2009 Feb 6;2:233-43. doi: 10.2147/dddt.s3181. Drug Des Devel Ther. 2009. PMID: 19920910 Free PMC article.

• Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.

  Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz M, Donato NJ. Wu J, et al. J Natl Cancer Inst. 2008 Jul 2;100(13):926-39. doi: 10.1093/jnci/djn188. Epub 2008 Jun 24. J Natl Cancer Inst. 2008. PMID: 18577747 Free PMC article.

• From Hen House to Bedside: Tracing Hanafusa's Legacy from Avian Leukemia Viruses to SRC to ABL and Beyond.

  Kharas MG, Daley GQ. Kharas MG, et al. Genes Cancer. 2010 Dec;1(12):1164-9. doi: 10.1177/1947601911407327. Genes Cancer. 2010. PMID: 21779439 Free PMC article.

• Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.

  Apperley JF, Cortes JE, Kim DW, Roy L, Roboz GJ, Rosti G, Bullorsky EO, Abruzzese E, Hochhaus A, Heim D, de Souza CA, Larson RA, Lipton JH, Khoury HJ, Kim HJ, Sillaber C, Hughes TP, Erben P, Van Tornout J, Stone RM. Apperley JF, et al. J Clin Oncol. 2009 Jul 20;27(21):3472-9. doi: 10.1200/JCO.2007.14.3339. Epub 2009 Jun 1. J Clin Oncol. 2009. PMID: 19487385 Free PMC article. Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Miscellaneous

  • NCI CPTAC Assay Portal